Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41

European Journal of Medicinal Chemistry

Volumn 106, Issue , 2015, Pages 34-43

  Rivero Buceta, Eva ^a   Doyagüez, Elisa G ^a   Colomer, Ignacio ^a   Quesada, Ernesto ^a   Mathys, Leen ^b   Noppen, Sam ^b   Liekens, Sandra ^b   Camarasa, María José ^a   Pérez Pérez, María Jesús ^a   Balzarini, Jan ^b   San Félix, Ana ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; TRYPTOPHAN DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEIN BINDING; TRYPTOPHAN; VIRUS RECEPTOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CLINICAL EVALUATION; DRUG SCREENING; DRUG STRUCTURE; GROWTH INHIBITION; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN INTERACTION; STRUCTURE ANALYSIS; TARGET CELL; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS REPLICATION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ANTI-HIV AGENTS; BINDING SITES; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, HIV; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN; TUMOR CELLS, CULTURED; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84947051881     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.10.031     Document Type: Article

References (51)

1. UNAIDS Report on the Global AIDS Epidemic 2013 November, 2013 Published http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf (accessed 8.10.15) K.M. De Cock H.W. Jaffe J.W. Curran The evolving epidemiology of HIV/AIDS AIDS 26 2012 1205e1213
2. Volberding S.G. Deeks Antiretroviral therapy and management of HIV infection Lancet 376 9734 2010 49 62
3. E. De Clercq Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 33 2009 307 320
4. st ed. 2005 Caister Academic Press Norwich
5. R.J. Pomerantz D.L. Horn Twenty years of therapy for HIV-1 infection Nat. Med. 9 2003 867 873
6. A.M. Margolis H. Heverling P.A. Pham A. Stolbach A review of the toxicity of HIV medications J. Med. Toxicol. 10 2014 26 39
7. J.C. Gaardbo H.J. Hartling J. Gerstoft S.D. Nielsen Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions Clin. Dev. Immunol. 670957 2012 1 17
8. T. Hawkins Understanding and managing the adverse effects of antiretroviral therapy Antivir. Res. 85 2010 201 209
9. M.P. Dube F.R. Sattler Inflammation and complications of HIV disease J. Infect. Dis. 201 2010 1783 1785
10. P. Rojas A. Holguín Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review J. Antimicrob. Chemother. 69 2014 2032 2042
11. G. Kumari R.K. Singh Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment Curr. Pharm. Des. 19 2013 1767 1783
12. F. Barré-Sinoussi A.L. Ross J.-F. Delfraissy Past, present and future: 30 years of HIV research Nat. Rev. Microbiol. 12 2013 877 883
13. C. Flexner HIV drug development: the next 25 years Nat. Rev. Drug. Discov. 6 2007 959 966
14. C. Tintori A. Brai A.L. Fallacara R. Fazi S. Schenone M. Botta Protein-protein interactions and human cellular cofactors as new targets for HIV therapy Curr. Opin. Pharmacol. 18 2014 1 8
15. A.A. Haqqani J.C. Tilton Entry inhibitors and their use in the treatment of HIV-1 infection Antivir. Res. 98 2013 158 170
16. M. Hertje M. Zhou U. Dietrich Inhibition of HIV-1 entry: multiple keys to close the door ChemMedChem 11 2010 1825 1835
17. C.B. Wilen J.C. Tilton R.W. Doms Molecular mechanisms of HIV entry Adv. Exp. Med. Biol. 726 2012 223 242
18. J.C. Tilton R.W. Doms Entry inhibitors in the treatment of HIV-1 infection Antivir. Res. 85 2010 91 100
19. I.P. Singh S.K. Chauthe Small molecule HIV entry inhibitors. Part II. Attachment and fusion inhibitors: 2004-2010 Expert Opin. Ther. Pat. 21 2011 399 416
20. D.R. Kuritzkes HIV-1 entry inhibitors: an overview Curr. Opin. HIV AIDS 4 2009 82 87
21. J.A. Esté Virus entry as a target for anti-HIV intervention Curr. Med. Chem. 10 2003 1617 1632
22. C.V. Fletcher Enfuvirtide, a new drug for HIV infection Lancet 361 2003 1577 1578
23. I.G. Williams Enfuvirtide (Fuzeon): the first fusion inhibitor Int. J. Clin. Pract. 57 2003 890 897
24. R.M. Gulick J. Lalezari J. Goodrich N. Clumeck E. DeJesus A. Horban J. Nadler B. Clotet A. Karlsson M. Wohlfeiler J.B. Montana M. McHale J. Sullivan C. Ridgway S. Felstead M.W. Dunne E. van der Ryst H. Mayer M.S. Tems Maraviroc for previously treated patients with R5HIV-1 infection N. Engl. J. Med. 359 2008 1429 1441
25. W.C. Greene Z. Debyser Y. Ikeda E.O. Freed E. Stephens W. Yonemoto R.W. Buckheit J.A. Esté T. Cihlar Novel targets for HIV therapy Antivir. Res. 80 2008 251 265
26. J.A. Esté T. Cihlar Current status and challenges of antiretroviral research and therapy Antivir. Res. 85 2010 25 33
27. For recent reviews, see: C. Teixeira J.R.B. Gomes P. Gomes F. Maurel Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug Eur. J. Med. Chem. 46 2011 979 992
28. A. Flores E. Quesada Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy Curr. Med. Chem. 20 2013 751 771
29. C.A. Didigu R.W. Doms Novel approaches to inhibit HIV entry Viruses 4 2012 309 324
30. K. Qian S.L. Morris-Natschke K.H. Lee HIV entry inhibitors and their potential in HIV therapy Med. Res. Rev. 29 2009 369 393
31. L. Saha HIV entry inhibitors: current status J. Clin. Diagn. Res. 2 2008 1119 1125
32. S. Nawale S. Neve V.J. Kadam M.P. Toraskar Emerging drug targets for HIV therapy: a review Int. J. ChemTech Res. 2 2010 1180 1185
33. M. Caffrey HIV envelope: challenges and opportunities for development of entry inhibitors Trends Microbiol. 19 2011 191 197
34. O. Francesconi C. Nativi G. Gabrielli I. De Simone S. Noppen J. Balzarini S. Liekens S. Roelens Antiviral activity of synthetic aminopyrrolic carbohydrate binding agents: targeting the glycans of viral gp120 to inhibit HIV entry Chem. Eur. J. 21 2015 10089 10093
35. T. Liu B. Huang P. Zhan E. De Clercq X. Liu Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806 Eur. J. Med. Chem. 86 2014 481 490
36. F. Sironi M. Malnati N. Mongelli P. Cozzi C. Guzzo S. Ghezzi C. Martínez-Romero A. García-Sastre P. Lusso D. Jabes P. Biswas Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains J. Transl. Med. 13 2015 107 122
37. M. Tiberi C. Tintori E.R. Ceresol R. Fazi C. Zamperini P. Calandro L. Franchi M. Selvaraj L. Botta M. Sampaolo D. Saita R. Ferrarese M. Clementi F. Canducci M. Botta Antimicrob. Agents Chemother. 58 2014 3043 3052
38. X.-Y. He L. Lu J. Qiu P. Zou F. Yu X.-K. Jiang L. Li S. Jiang S. Liu L. Xie Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41 Bioorg. Med. Chem. 21 2013 7539 7548
39. V. Lozano L. Aguado B. Hoorelbeke M. Renders M.J. Camarasa D. Schols J. Balzarini A. San-Félix M.J. Pérez-Pérez Targeting HIV entry through interaction with envelope glycoprotein 120 (gp120): synthesis and antiviral evaluation of 1,3,5-triazines with aromatic amino acids J. Med. Chem. 54 2011 5335 5348
40. G.R. Newkome R.J. Behera C.N. Moorefield G.R. Baker Cascade polymers: syntheses and characterization of one-directional arborols based on adamantine J. Org. Chem. 56 1991 7162 7167
41. B.M. O'Leary T. Szabo N. Svenstrup C.A. Schalley A. Lützen M. Schäfer J. Rebek Jr. gFlexiballg toolkit: a modular approach to self-assembling capsules J. Am. Chem. Soc. 123 47 2001 11519 11533
42. L. Fernández M. Calderón M. Martinelli M. Strumia H. Cerecetto M. González J.J. Silber M. Santo Evaluation of a new dendrimeric structure as prospective drugs carrier for intravenous administration of antichagasic active compounds J. Phys. Org. Chem. 21 2008 1079 1085
43. T. Zhou H. Neubert D.Y. Liu Z.D. Liu Y.M. Ma X.L. Kong W. Luo S. Mark R.C. Hider Iron binding dendrimers: a novel approach for the treatment of haemochromatosis J. Med. Chem. 49 2006 4171 4182
44. C. Ornelas J. Broichhagen M. Weck Strain-promoted alkyne azide cycloaddition for the functionalization of poly(amide)-based dendrons and dendrimers J. Am. Chem. Soc. 132 2010 3923 3931
45. C. Akpo E. Weber J. Reiche Synthesis, Langmuir and Langmuir-Blodgett film behavior of new dendritic amphiphiles New J. Chem. 2006 1820 1833
46. M. Baba R. Pauwels J. Balzarini J. Arnout J. Desmyter E. De Clercq Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro Proc. Natl. Acad. Sci. 85 1988 6132 6136
47. J. Balzarini K.V. Laethem D. Daelemans S. Hatse A. Bugatti M. Rusnati Y. Igarashi T. Oki D. Schols Pradimicin A, a carbohydrate-binding nonpeptidic lead compounds for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus J. Virol. 81 2007 362 373
48. J. Balzarini A. Holý J. Jindrich L. Naesens R. Snoeck D. Schols E. De Clercq Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine Antimicrob. Agents Chemother. 37 1993 332 338
49. R. Pauwels K. Andries J. Desmyter D. Schols M.J. Kukla H.J. Breslin A. Raeymaeckers J. Van Gelder R. Woestenborghs J. Heykants K. Schellekens M.A.C. Janssen E. De Clercq P.A.J. Janssen Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives Nature 343 1990 470 474
50. D. Daelemans R. Pauwels E. De Clercq C. Pannecouque A time-of-drug addition approach to target identification of antiviral compounds Nat. Protoc. 6 2011 925 933
51. T. Mizuochi M.W. Spellman M. Larkin J. Solomon L.J. Basa T. Feizi Carbohydrate structures of the human immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells Biochem. J. 254 1988 599 603